Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1834
http://purl.obolibrary.org/obo/NCIT_C1834
|
|---|---|
| Preferred Name | Cilengitide |
| Definitions |
A cyclic Arg-Gly-Asp peptide with potential antineoplastic activity. Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and alpha(v)beta(5) integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI04)
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A cyclic Arg-Gly-Asp peptide with potential antineoplastic activity. Cilengitide binds to and inhibits the activities of the alpha(v)beta(3) and alpha(v)beta(5) integrins, thereby inhibiting endothelial cell-cell interactions, endothelial cell-matrix interactions, and angiogenesis. (NCI04) |
|---|---|
| prefLabel | Cilengitide
|
| label | Cilengitide
|
| PDQ_Closed_Trial_Search_ID | 37844
|
| code | C1834
|
| Has_Target | |
| prefixIRI | NCIT:C1834
|
| in_subset |
See more
See less
|
| Display_Name | Cilengitide
|
| Preferred_Name | Cilengitide
|
| FDA_UNII_Code | 4EDF46E4GI
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C27H40N8O7
|
| Maps_To | Cilengitide
|
| CAS_Registry | 188968-51-6
|
| NSC Number | 707544
|
| NCI_Drug_Dictionary_ID | 37844
|
| Legacy Concept Name | Cilengitide
|
| type | |
| ALT_DEFINITION | A substance that is being studied as an anticancer and antiangiogenesis drug.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 37844
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C0971473
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |